SAN DIEGO, April 24, 2017 /PRNewswire/ -- ViaCyte,
Inc., a privately-held regenerative medicine company, today
announced two presentations on April
27 at the Alliance for Regenerative Medicine's 5th Annual
Cell & Gene Therapy Investor Day in Boston. ViaCyte is
developing novel stem cell-derived islet replacement therapies for
insulin-requiring diabetes. The company's lead
PEC-Direct™ product candidate is entering clinical
development as a potential functional cure for patients with type 1
diabetes with the highest risk of life threatening acute
complications. The related PEC-Encap™ product
candidate in development has the potential to provide a functional
cure for essentially all patients with type 1 diabetes as well as
become an important therapy for patients with type 2 diabetes that
depend on insulin to help control their disease.
A live webcast at the 5th Annual Cell & Gene Therapy
Investor Day will be available at the time of the presentations
here: http://www.arminvestorday.com/webcast.
ViaCyte will also present at the upcoming World Advanced
Therapies and Regenerative Medicine Congress in London on May
19.
Details of the presentations are as follows:
Event:
|
5th Annual Cell
& Gene Therapy Investor Day
|
Speaker:
|
Dr. Paul Laikind,
President and Chief Executive Officer
|
Panel:
|
Cell Therapy Beyond
Oncology: Where Does the Greatest Potential Lie?
|
Date/Time:
|
April 27, 10:25 AM
EDT
|
Location:
|
The State Room,
Boston
|
|
|
Event:
|
5th Annual Cell
& Gene Therapy Investor Day
|
Speaker:
|
Dr. Mark Zimmerman,
Vice President, Strategy and Business Development
|
Fireside
Chat:
|
Hosted by Edward
Tenthoff, Managing Director & Senior Research Analyst, Piper
Jaffray
|
Date/Time:
|
April 27, 5:00 PM
EDT
|
Location:
|
The State Room,
Boston
|
|
|
Event:
|
World Advanced
Therapies and Regenerative Medicine Congress
|
Speaker:
|
Dr. Mark Zimmerman,
Vice President, Strategy and Business Development
|
Date/Time:
|
May 19, 9:40 AM
BST
|
Location:
|
Business Design
Centre, London
|
For more information about ViaCyte's participation in industry
events, please visit:
http://viacyte.com/news-events-2/viactye-events/
About ViaCyte
ViaCyte is a privately-held regenerative medicine company
developing novel cell replacement therapies as potential long-term
diabetes treatments to reduce the risk of hypoglycemia and
diabetes-related complications. ViaCyte's product candidates
are based on the derivation of pancreatic progenitor cells, which
are then implanted in durable and retrievable cell delivery
devices. Once implanted and matured, these cells are designed
to secrete insulin and other pancreatic hormones in response to
blood glucose levels. ViaCyte has two products in
development. The PEC-Direct™ product candidate delivers the
pancreatic progenitor cells in a non-immunoprotective device that
allows direct vascularization of the implant in order to insure a
robust and consistent engraftment and is being developed for type 1
diabetes patients who have severe hypoglycemic episodes, extreme
glycemic lability, and/or impaired awareness of hypoglycemia.
The PEC-Encap™ (also known as VC-01) product candidate is designed
to deliver the same pancreatic progenitor cells in an
immunoprotective device and is currently in active development as a
therapy for all patients with type 1 diabetes as well as insulin
requiring patients with type 2 disease. ViaCyte is
headquartered in San Diego,
California with additional operations in Athens, Georgia. The Company is funded
in part by the California Institute for Regenerative Medicine
(CIRM) and JDRF. For more information on ViaCyte, please
visit www.viacyte.com and connect with ViaCyte on Twitter and
Facebook.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/viacyte-to-present-at-arms-5th-annual-cell--gene-therapy-investor-day-in-boston-300443997.html
SOURCE ViaCyte, Inc.